Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers

Koller, M., Qiu, S-Q., Linssen, M. D., Jansen, L., Kelder, W., de Vries, J., Kruithof, I., Zhang, G-J., Robinson, D. J., Nagengast, W. B., Jorritsma-Smit, A., van der Vegt, B. & van Dam, G. M., 18-Sep-2018, In : Nature Communications. 9, 1, 11 p., 3739.

Research output: Contribution to journalArticleAcademicpeer-review

During the last decade, the emerging field of molecular fluorescence imaging has led to the development of tumor-specific fluorescent tracers and an increase in early-phase clinical trials without having consensus on a standard methodology for evaluating an optical tracer. By combining multiple complementary state-of-the-art clinical optical imaging techniques, we propose a novel analytical framework for the clinical translation and evaluation of tumor-targeted fluorescent tracers for molecular fluorescence imaging which can be used for a range of tumor types and with different optical tracers. Here we report the implementation of this analytical framework and demonstrate the tumor-specific targeting of escalating doses of the near-infrared fluorescent tracer bevacizumab-800CW on a macroscopic and microscopic level. We subsequently demonstrate an 88% increase in the intraoperative detection rate of tumor-involved margins in primary breast cancer patients, indicating the clinical feasibility and support of future studies to evaluate the definitive clinical impact of fluorescence-guided surgery.

Original languageEnglish
Article number3739
Number of pages11
JournalNature Communications
Issue number1
Publication statusPublished - 18-Sep-2018



Download statistics

No data available

ID: 65487399